MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals Inc. is projected to achieve core business revenues exceeding $1 billion, driven by anticipated revenue growth from its main product, Livmarli, which is expected to generate over $800 million by 2031. The company's financial outlook is bolstered by anticipated 69% year-over-year growth in Livmarli sales for FY25, supported by new patient additions and growth in the adult PFIC patient population, alongside a 31% year-over-year increase in its bile acid portfolio. Furthermore, there are expectations for expanded market opportunities through the success of pipeline programs and increased diagnosis rates, which could enhance revenue beyond initial estimates, particularly in rare cholestatic pruritus conditions.

Mirum Pharmaceuticals faces a negative outlook primarily due to the potential for unexpected safety events and weaker-than-expected drug efficacy, which could hinder the advancement of its clinical trials and market success. Increased operating expenses and cash burn raise concerns regarding the need for more frequent equity issuances, potentially at unattractive valuations that affect shareholder interests. Additionally, risks related to regulatory approvals, competitive pressure, and safety signals are likely to restrict the company's revenue generation capabilities and threaten long-term growth projections.